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Abstract
Background: Almost one third of women suffer continuous lower back pain during labour. Evidence from three
systematic reviews demonstrates that sterile water injections (SWI) provide statistically and clinically significant pain
relief in women experiencing continuous lower back pain during labour. The most effective technique to
administer SWI is yet to be determined. Therefore, the aim of this study is to determine if the single injection SWI
technique is no less effective than the routinely used four injection SWI method in reducing continuous lower
back pain during labour.
Methods/design: The trial protocol was developed in consultation with an interdisciplinary team of clinical
researchers. We aim to recruit 319 women presenting at term, seeking analgesia for continuous severe lower back pain
during labour. Participants will be recruited from two major maternity hospitals in Australia. Randomised participants are
allocated to receive a four or single intradermal needle SWI technique. The primary outcome is the change in self-
reported pain measured by visual analogue scale at baseline and thirty minutes post intervention. Secondary outcomes
include VAS change scores at 10, 60, 90 and 120 min, analgesia use, mode of birth and maternal satisfaction.
Statistical analysis: Sample size was calculated to achieve 90% power at an alpha of 0.025 to detect a non-
inferiority margin of ≤ 1 cm on the VAS, using a one-sided, two-sample t-test. Baseline demographic and clinical
characteristics will be analysed for comparability between groups. Differences in primary (VAS pain score) and
secondary outcomes between groups will be analysed by intention to treat and per protocol analysis using
Student’s t-test and ANOVA.
Conclusion: This study will determine if a single intradermal SWI technique is no less effective than the routinely
used four injection technique for lower back pain during labour. The findings will allow midwives to offer women
requesting SWI during labour an evidence-based alternative technique more easily administered by staff and
accepted by labouring women.
Trial Registration: ACTRN12609000964213
Background
Almost one in three (30%) women in labour suffer from
continuous lower back pain [1]. This pain is often asso-
ciated with varying degrees of fetal malposition, particu-
larly occipito-posterior position, which may apply
pressure on pain-sensitive structures within the pelvis
[2]. Characteristically, the pain persists throughout the
normal painless resting intervals between contractions
and is associated with greater analgesic requirement [2].
Administration of Sterile Water Injections (SWI) into
the lower back is used in midwifery to provide pain
relief to women experiencing lower back pain during
labour. The sterile water causes osmotic and mechanical
irritation resulting in a brief (15-30 second) and signifi-
cant stinging sensation. The onset of pain relief follows
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The procedure can be repeated a number of times [3].
The therapeutic effect has been explained by gate con-
trol theory [4] whereby the painful stinging stimulates
competing nerve fibres, creating a block to the slower
visceral signals from uterine contractions and back pain.
T h em o s tf r e q u e n t l yu s e dS W It e c h n i q u ec o n s i s t so f
four intradermal injections into the skin surrounding
the Michaelis rhomboid over the sacral area.
Systematic reviews [3,5] and meta-analysis [6] have
reported a significant reduction in self-reported pain
measures in groups receiving SWI compared with con-
trols. Authors concluded that SWI are an effective ther-
apeutic intervention for the management of continuous
back pain during labour. However, the included rando-
mised controlled trials (RCT) were heterogeneous and
incorporated different SWI techniques (single and four-
injection SWI methods), methods of administration
(intradermal or subcutaneous), and comparison groups
(normal saline, transcutaneous electronic nerve stimula-
tion and “standard care” defined as massage, counter
pressure and water immersion). Authors of the systema-
tic reviews [3,5] highlight that the analgesic efficacy
obtained following administration of a single SWI at the
most painful point [7] appear comparable to that
obtained using the four injection SWI technique. The
analgesic benefit of the single SWI method is further
supported by results of a more recent randomised con-
trolled trial (RCT) [8] which compared a single SWI to
a placebo. The comparable analgesic benefit observed
for both techniques has led authors to conclude there is
need for further research [3,5]. There have been no
trials conducted to date comparing the two SWI
techniques.
There may be important clinical benefits in demon-
strating the comparable analgesic efficacy of a single
versus four needle SWI technique. The relative reduc-
tion in discomfort associated with the single injection
procedure may increase the woman’s satisfaction and
acceptability with SWI treatment during labour, and
willingness to use the procedure again in the future. In
addition, improved resource allocation can be expected
as only one midwife is required to administer a single
SWI compared with the current recommendation for
two midwives to administer the four injection technique.
T h e r e f o r e ,t h ea i mo ft h i ss t u d yi st oc o m p a r eas i n g l e
intradermal SWI technique with the standard four injec-
tion intradermal technique in the degree and duration
of analgesic benefit.
Methods/design
A randomised, controlled, non-inferiority design was
considered most appropriate method to answer our sta-
ted aim. Where two treatments, have both previously
been shown to be superior to a placebo, and/or in cases
where the use of a placebo may be unethical or imprac-
tical, a non inferiority design can be used to determine
if one treatment is “no worse” than the other[9,10].
Usually, as in this study, the interventions include a new
treatment and an active comparator, or a treatment cur-
rently in use. In relation to this trial, the single injection
is the new treatment and the four injection technique is
the active comparator. The null hypothesis is not proven
if the measured effects of the two treatments lie within a
specified non-inferiority margin [11].
Hypothesis
The null hypothesis is conventionally stated in an RCT
which assumes that there is no difference between the
intervention group and controls. The null hypothesis
places the onus on the intervention to be proven [12].
The null hypothesis is accepted if it cannot be refuted at
the ap r i o r idefined level of significance. However, a
non-inferiority design is attempting to show that two
active treatments are similar in effect [13]. Therefore,
the null hypothesis cannot be rejected if the measured
treatment effects lie within a pre-specified non-inferior-
ity margin [11]. Within non-inferiority design the sam-
ple size must be robust enough to test the quantitative
or clinically relevant margin or definition of non-infer-
iority [13]. This margin is informed by considerations of
clinically relevance, with any treatment differences fall-
ing outside this range indicating that any dissimilarity
between treatments is unacceptably large [9].
The predefined non-inferiority margin for the present
study was defined by the minimal clinically (i.e. not sta-
tistically) significant difference in the Visual Analogue
Scale (VAS) to measure self-reported pain. Therefore,
the null hypothesis (H0) would be “treatment is infer-
ior”, the alternative hypothesis (HA) “treatment is non-
inferior":
H0: Difference between the four injection intrader-
mal SWI and single injection intradermal SWI is ≥ 1
cm on the 10 cm VAS
HA: Difference between the four injection intrader-
mal SWI and single injection intradermal SWI is < 1
cm on the 10 cm VAS
Study site and population
The study population will be recruited from the Birth
Suites of two major maternity hospitals. Women eligible
for the study are those that request analgesia for contin-
uous severe lower back pain during labour (≥7o nt h e
VAS) and provide informed consent. The categorisation
of severe back pain as ≥7 on the VAS has been pre-
viously validated [14] and consistent with defined
Lee et al. BMC Pregnancy and Childbirth 2011, 11:21
http://www.biomedcentral.com/1471-2393/11/21
Page 2 of 9inclusion criteria in previous SWI studies [14-17].
Women with a baseline VAS score of <7 were more
likely to find administration of the procedure unaccepta-
ble [16].
The eligibility criteria are pre-specified as:
Inclusion criteria
Participants eligible for the study will be defined as:
Women at term (between 37 and 42 weeks)
Nulliparous or multiparous
Singleton pregnancy
Cephalic presentation
First stage labour (spontaneous or induced)
No previous analgesia pharmacological analgesia
(nitrous oxide inhalation, narcotics)
Back pain assessed by VAS as ≥7
Ability to give informed consent. This may exclude
women of non-English speaking backgrounds, where
an interpreter is unavailable, and those women
whose consent is required to be provided by a par-
ent or guardian.
Exclusion criteria
Gestation <37 weeks
Multiple pregnancy
Malpresentation (Breech Transverse etc.)
Second stage labour
Pharmacological analgesia prior to SWI
Back pain assessed by VAS <7
Women whose labour would be considered high
risk.
Interventions
Control group
Participants randomised to the control group will be
given SWI using the standard four injection intradermal
technique into the skin surrounding the Michaelis
rhomboid over the sacral area. Anatomically, the injec-
tions will be administered: two over each posterior
superior iliac spine (PSIS) and two three cm below and
one cm medial to the PSIS (Figure 1). Minor discrepan-
cies or changes to the anatomical position or alignment
of the four injections have not been shown to impact on
any analgesic effect [18].
Intervention group
Participants randomised to the intervention group will
be given SWI using the single injection intradermal
technique.
The anatomical site for the single injection will be
over the single most painful point as indicated by the
woman (Figure 2).
Primary outcome
Decrease in pain measured by VAS at 30 minutes post-
intervention.
Secondary outcomes
Secondary outcomes will include:
a) Pain score measured by VAS 10, 60, 90 and 120
mins post-intervention
b) Level of administration discomfort associated with
SWI procedure (measured by VAS at 10 minutes
post SWI)
c) Subsequent analgesia use (pharmacological and
non-pharmacological)
d) Mode of birth
e) Likelihood to use again with subsequent labour
f) Patient satisfaction with analgesic effect
Sample size
A sample size of 133 in each group will be required to
achieve 90% power to detect non-inferiority using a
one-sided, two-sample t-test. The significance (alpha) of
the test is 0.025. The non-inferiority margin is ≤ 1c m
on the VAS and the true difference between the means
Figure 1 The four injection technique.
Figure 2 T h es i n g l ei n j e c t i o nt e c h n i q u e .W o m a ni n d i c a t e st h e
most painful point or central to the most painful area.
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of ± 2.5 on the VAS was conservatively estimated from
results reported in a recent meta-analysis [6] of SWI
studies. As consent and randomisation will occur in the
birth suite, attrition is expected to be minimal. However,
we have estimated a 20% attrition to account for cases
of precipitate birth prior to the assessment of the pri-
mary outcome, or other unforseen reasons for withdra-
wal such as emergency caesarean section. Thus a total
of 319 participants will be required.
Recruitment of participants
Trial participation is invited through public antenatal
clinics, antenatal education classes and on the Birth
Suites at both recruiting hospitals. Although both sites
use a number of models of care in the provision of
maternity services, all women return to the public
antenatal clinic at a particular gestation; 36 weeks and
30 weeks at the Site One and Site Two, respectively. At
this time women will be provided with information
regarding the trial. The recruitment strategy aims to
provide information regarding the trial prior to presen-
tation to the Birth Suite in labour.
Consent
The recruitment strategies are designed to ensure that
women receive information regarding SWI as an inter-
vention for back pain and information on the trial, at or
before 36 weeks gestation (i.e. prior to inclusion criteria
of 37-42 weeks gestation). The majority of women will
consent to the trial on presentation to the Birth Suite in
labour at both sites. Clinical midwives and/or clinical
facilitators from both sites will be available to receive
informed consent. A trial investigator will be available
v i am o b i l ep h o n et op r o v i d es u p p o r tf o rm i d w i v e s
undertaking consent and enrolment procedures, and to
promote continuity of procedures and trial fidelity
across the two sites. Women who have been provided
with a participant information sheet and indicate an
interest in joining the trial will be able to contact the
research midwife or investigators for further information
or clarification before consent. A video demonstrating
the four injection technique is available for women to
access at the trial website. http://maternity.mater.org.au/
switch. A form will be placed with the woman’s chart to
highlight that the woman has consented to participate
in the study if eligibility criteria is met. Verbal consent
will be re-affirmed immediately prior to randomisation
and documented within in the woman’s clinical chart.
Women are able to withdraw consent at any time (i.e.
before, during or after the procedure and/or before
completing follow-up questionnaire) without affecting
their usual clinical care or request alternative and avail-
able means of analgesia.
Randomisation
The randomisation schedule for Site One will be pre-
pared by a statistician using a computer-generated list
of random numbers. Blinding of allocation to the study
intervention will be undertaken using opaque sealed
envelopes prepared by Site One administrative staff. A
separate randomisation sequence was generated for Site
Two in permuted blocks of four to ensure an equal
number of participants across both arms of the trial
where smaller recruitment numbers are expected.
Blinded allocation at this site will be undertaken using
similarly prepared opaque sealed envelopes (Figure 3).
Blinding
At both sites, the envelopes will be kept in a locked cup-
board on the birth suite and available for randomisation
24 hours/day. The key will be held by the Midwifery
Team Leader who will obtain and open one envelope,
then with the assistance of another midwife will adminis-
ter the SWI using the technique detailed within the
envelope. The two midwives will be present during the
procedure regardless of the SWI technique being admi-
nistered, to assist with blinding of the procedure to the
midwife providing care and collecting data. The injection
site(s) will be covered with a hypoallergenic opaque dres-
sing to prevent visualisation of the number of injections
used. The participants will be aware not to discuss the
type of intervention they were allocated to with their
midwife. The midwife caring for the woman will then
return to collect the intervention data.
Data collection
Upon randomisation the attending Midwife will docu-
ment the following data:
￿ UR number
￿ Gravity and Parity
￿ Gestation
￿ Spontaneous or induced labour
￿ Findings of last vaginal exam and time
￿ VAS score and time
￿ Time of administration
Following administration of SWI the following data
will be recorded:
￿ VAS related to analgesia effect at 10 mins
￿ VAS related to discomfort felt during the proce-
dure (at 10 mins)
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vals up to 2 hours post procedure
At Site One the following data will be extracted from
the obstetric database by the research midwife following
birth:
￿ Age
￿ Booking weight & BMI
￿ Mode of birth
￿ Time of birth
￿ Any other analgesia used (pharmacological and
non pharmacological)
￿ Model of care
￿ Educational level
The obstetric databases at Site One and Site Two vary
slightly in the data items collected. As separate data col-
lection forms have been generated for the randomisation
process for Site Two, the data collection forms have
been amended to account for any differences in infor-
mation captured by the database.
The following self-reported data will be sought from
the woman within 48 hours following birth:
￿ Perceived satisfaction with SWI administration
￿ Perceived satisfaction with SWI analgesic benefit
￿ Likelihood to use again with subsequent labour
￿ Likelihood to recommend to SWI to others
Data will be collected by the Midwife caring for the
labouring woman then returned to a securely locked
cupboard. Completed data forms will be de-identified
and entered into a password protected electronic data-
base. Identified data collection forms will be kept in
locked storage for 15 years. Data collection forms at the
second site will be stored in a locked cupboard and col-
lected on a fortnightly basis. Data will be entered into a
Microsoft Excel spreadsheet and transmitted as a pass-
word protected file
Data collection tools
The intrapartum data collection tool has been adapted
from an existing document that was used as an audit
Figure 3 Randomisation and participant flow.
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reported postnatal data, the data collection tool pre-
viously published and used in the Australian study by
Peart et al. [16] has been made available for use. This
tool has been tested for face readability, language and
face validity. The instrument will be administered by a
researcher blinded to the particular technique used.
Statistical analysis
Demographic and other baseline characteristics will be
analysed for comparability between groups to assess the
adequacy of randomisation. Differences in VAS pain score
between the two groups will be analysed using Student’st -
test and analysis of variance (non-parametric tests used if
data is highly clustered toward extremes). Data analysis for
the primary outcome will determine if the treatment effect
lies within the a priori defined non-inferiority margin (± 1
cm) and the null effect (0 cm) at a one-sided alpha of
0.025. The pre-specified non-inferiority margin was based
on a one cm (95% CI 0.6-1.4 cm) minimally clinically sig-
nificant difference reported for VAS in severe pain [14].
The Mann-Whitney U test will be utilised for non-para-
metric data and chi-squared test for categorical variables.
Women who give birth or elect for narcotic and/or regio-
nal analgesia after the collection of the primary measure
(VAS score 30 minutes post injection) but before the com-
pletion of the secondary outcomes (VAS up to 120 mins)
will be included in the trial. Women giving birth or elect-
ing for narcotic and/or regional anaesthesia prior to the
collection of the primary outcome measure will be
included in the Intention to Treat (ITT) analysis. The con-
servative nature of ITT may obscure differences between
treatments groups therefore increasing the chance of fal-
sely declaring equivalence [19]. To address this, some
authors have recommended that Per Protocol (PP) analysis
also be conducted alongside ITT to provide a more robust
conclusion if both methods support the non-inferiority
[9,20]. Other authors [21] argue that the benefits of ITT
analysis continue to outweigh the PP approach. As it is
unlikely that participants in this trial will cross from one
intervention to another, the ITT approach will be used
unless the dropout out rate exceeds the estimated margin
allowed of 20%. Should the dropout rate exceed 20% then
a PP analysis will also be conducted. Figure 4 outlines pos-
sible scenarios for the outcome of the data analysis based
on the pre-defined noninferiority margin, indicated as the
shaded area. Error bars indicate 90% confidence intervals
(CI). If the CI is completely to the left of zero, the treat-
ment is inferior (scenario A). Scenarios C,D and E indicate
noninferiority as the CI lies within the specified margin
(shaded area). Scenario F would indicate superiority. An
inconclusive result (scenario B) is unlikely as the sample
size is sufficiently powered to provide a result [22].
In the event that women experience no relief from the
single injection and request the four injection technique,
these women will remain within the study, and the data
will be analysed according to ITT and per protocol
principles.
Women requesting a repeat injection will receive the
standard four injection technique. A pre-injection VAS
score will be sought prior to administration and post
injection VAS score will be collected at 30 minutes.
These will be reported separately.
Confidentiality and data security
The data is de-identified, coded and entered onto a
password protected database.
Data safety monitoring board
A Data Safety Monitoring Board has not been estab-
lished for this trial. As there have been no adverse
events reported in any previous trial on the topic, the
trial was considered to be low risk. However, a senior
obstetrician at both sites has agreed to act as a clinical
monitor to investigate any adverse events that may be
associated with the trial. This process has been approved
by the Human Research Ethics Committee at each site.
Project management
Project management will be overseen by the research
team that consists of midwifery and obstetric clinicians,
midwifery academics and researchers from both sites.
The research team will meet regularly during the pro-
jects development phase and regular contact and pro-
gress reports maintained via email during the
recruitment phase of the trial.
Ethical issues
Human Research Ethics Committee (HREC) Approval
Mater Health Services HREC No:1422M
Australian Catholic University HREC No:Q2009 48
Royal Brisbane and Women’s Hospital HREC No:
HREC/10/QRBW/155
Women of Non-English Speaking Backgrounds (NESB) and
minors
At both sites, an onsite interpreter service is available
during “office hours” for the most common language
groups of Vietnamese and Mandarin/Cantonese with
contract interpreters for eighteen other languages avail-
able. At other times the Birth Suite accesses a telephone
interpreter service. For NESB women considering SWI
as an intervention for back pain, the interpreter service
accessed at the time will be utilised to provide informa-
tion and gain consent for inclusion in the trial. To sup-
plement this, copies of the Participant Information
Sheet and consent form will be available in Vietnamese
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interpreter cannot be found, inclusion in the trial will
not be offered. Postnatal data will be collected using this
method as interpreters are required when providing rou-
tine postnatal information.
Potential risks
The four injection SWI technique is routinely used in
the birth suites at Site One. Therefore, no additional
risks from study participation would be expected. More-
over, no allergic or systemic reactions to the procedure
have been reported in the literature other than the brief
stinging sensation immediately following administration
[5].
Discussion
T h i ss t u d ye m p l o y sar a n d o m i s e dc o n t r o l l e dn o n - i n f e r -
iority design determining if the single SWI technique is
non-inferior to the four SWI technique more commonly
used in clinical practice. This research gap was identi-
fied in the literature.
The project has the potential to make a significant
contribution to maternity and midwifery research and
Figure 4 Possible scenarios of observed treatment differences [adapted from [22]]. Shaded area indicates non-inferiority margin.
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care is offered in a diverse range of settings and models
of care, offering different services and options in terms
of pain management. Many women may not have access
to narcotics and epidural analgesia, or these forms of
analegisia may be unacceptable due to actual or per-
ceived side effects or cultural considerations. The imple-
mentation of a best practice, evidenced based SWI
technique for the relief of back pain in labour will pro-
vide an alternative analgesic option that addresses con-
sumer demand for low intervention strategies. The
procedure is not technology dependent, relatively sim-
ple, and may be an effective and feasible analgesic strat-
egy suitable for any maternity care setting or model.
Therefore, this trial will make a significant contribution
to the evidence supporting the most effective adminis-
tration of SWI. Important clinical (e.g. increased
women’s satisfaction/acceptability of SWI administra-
tion) and cost benefits (e.g. reduced staff/time required
for administration) might be expected if the analgesic
efficacy of the single needle technique can be shown to
be no less effective than the four injection method.
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